Cargando…
Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT-III: A pilot study
The anticoagulation effect of heparin requires adequate serum antithrombin (AT)-III levels. Rivaroxaban, however, exhibits its anticoagulation effects independent of AT-III. The aim of the present study was to evaluate the efficacy and safety of rivaroxaban as a treatment for venous thromboembolism...
Autores principales: | Zhang, Lihua, Zhang, Haitao, Zhang, Jiong, Tian, Hong, Liang, Ju, Liu, Zhihong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772665/ https://www.ncbi.nlm.nih.gov/pubmed/29399079 http://dx.doi.org/10.3892/etm.2017.5471 |
Ejemplares similares
-
Rivaroxaban for cancer-associated venous thromboembolism
por: Liang, Bo, et al.
Publicado: (2021) -
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for
Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2018) -
Fatigue after initiating rivaroxaban for venous thromboembolism
por: Karlsvik, Tina Margrethe, et al.
Publicado: (2020) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020) -
Rivaroxaban in acute venous thromboembolism: UK prescribing experience
por: Speed, Victoria, et al.
Publicado: (2021)